Top

Published in:

01-11-2007 | Review

New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment

Authors: Jonathan P. Sleeman, Natascha Cremers

Published in: Clinical & Experimental Metastasis | Issue 8/2007

Abstract

The currently prevailing ideas that set out to explain the process of metastasis are largely based on observations made on the total tumor cell population, and often focus on tumor-intrinsic properties. The clinical observation that particular tumor types show a predilection to metastasize to particular organs has been understood in terms of Paget’s “Seed and Soil” hypothesis, but a definition of the molecular basis for the “Seed and Soil” hypothesis is at best only partial. Recent ideas about the cellular basis of tumor growth (cancer stem cells) and the remote establishment by primary tumors of special permissive microenvironments in target organs prior to metastasis (pre-metastatic niches) have the potential to radically change our view of the metastatic process. In this review we examine these new concepts with a particular emphasis on findings made in the context of breast cancer, and compare these concepts with ideas based on studies using the total tumor cell population.

Sleeman JP (2000) The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 157:55–81PubMed

Fidler IJ (2002) Critical determinants of metastasis. Semin Cancer Biol 12:89–96PubMedCrossRef

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453–458PubMedCrossRef

Bernards R, Weinberg RA (2002) A progression puzzle. Nature 418:823PubMedCrossRef

van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef

van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009PubMedCrossRef

Weigelt B, Glas AM, Wessels LF et al (2003) Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100:15901–15905PubMedCrossRef

Weigelt B, Hu Z, He X et al (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65:9155–9158PubMedCrossRef

Kang Y, Siegel PM, Shu W et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549PubMedCrossRef

10.

Minn AJ, Kang Y, Serganova I et al (2005) Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 115:44–55PubMed

11.

Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524PubMedCrossRef

12.

Kang Y, He W, Tulley S et al (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102:13909–13914PubMedCrossRef

13.

Deckers M, van Dinther M, Buijs J et al (2006) The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 66:2202–2209PubMedCrossRef

14.

Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131–142PubMedCrossRef

15.

Berx GER, Christofori G et al (2007) Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer. Clin Exp Metastasis

16.

Dalerba P, Cho RW, Clarke MF (2007) Cancer stem cells: models and concepts. Annu Rev Med 58:267–284PubMedCrossRef

17.

Kelly PN, Dakic A, Adams JM et al (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317:337PubMedCrossRef

18.

Kruger JA, Kaplan CD, Luo Y et al (2006) Characterization of stem cell-like cancer cells in immune-competent mice. Blood 108:3906–3912PubMedCrossRef

19.

Ghods AJ, Irvin D, Liu G et al (2007) Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645–1653PubMedCrossRef

20.

Li Y, Welm B, Podsypanina K et al (2003) Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA 100:15853–15858PubMedCrossRef

21.

Roy M, Pear WS, Aster JC (2007) The multifaceted role of Notch in cancer. Curr Opin Genet Dev 17:52–59PubMedCrossRef

22.

Clement V, Sanchez P, de Tribolet N et al (2007) HEDGEHOG-GLI1 Signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165–172PubMedCrossRef

23.

Piccirillo SG, Reynolds BA, Zanetti N et al (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444:761–765PubMedCrossRef

24.

Burkert J, Wright NA, Alison MR (2006) Stem cells and cancer: an intimate relationship. J Pathol 209:287–297PubMedCrossRef

25.

Li F, Tiede B, Massague J et al (2007) Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17:3–14PubMedCrossRef

26.

Al-Hajj M, Becker MW, Wicha M et al (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14:43–47PubMedCrossRef

27.

Phillips TM, McBride WH, Pajonk F (2006) The response of CD24(−/low)/CD44⁺ breast cancer-initiating cells to radiation. J Natl Cancer Inst 98:1777–1785PubMedCrossRef

28.

Abraham BK, Fritz P, McClellan M et al (2005) Prevalence of CD44⁺/CD24⁻/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11:1154–1159PubMed

29.

Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988PubMedCrossRef

30.

Ponti D, Costa A, Zaffaroni N et al (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65:5506–5511PubMedCrossRef

31.

Shipitsin M, Campbell LL, Argani P et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259–273PubMedCrossRef

32.

Brabletz T, Jung A, Spaderna S et al (2005) Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5:744–749PubMedCrossRef

33.

Lugo TG, Braun S, Cote RJ et al (2003) Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol 21:2609–2615PubMedCrossRef

34.

Balic M, Lin H, Young L et al (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 12:5615–5621PubMedCrossRef

35.

Sheridan C, Kishimoto H, Fuchs RK et al (2006) CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8:R59PubMedCrossRef

36.

Liu R, Wang X, Chen GY et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356:217–226PubMedCrossRef

37.

Gotte M, Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66:10233–10237PubMedCrossRef

38.

Lopez JI, Camenisch TD, Stevens MV et al (2005) CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 65:6755–6763PubMedCrossRef

39.

Kaufmann M, Heider KH, Sinn HP et al (1995) CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345:615–619PubMedCrossRef

40.

Sinn HP, Heider KH, Skroch-Angel P et al (1995) Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res Treat 36:307–313PubMedCrossRef

41.

Tempfer C, Losch A, Heinzl H et al (1996) Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7–8 in human breast cancer. Eur J Cancer 32A:2023–2025PubMedCrossRef

42.

Jansen RH, Joosten-Achjanie SR, Arends JW et al (1998) CD44v6 is not a prognostic factor in primary breast cancer. Ann Oncol 9:109–111PubMedCrossRef

43.

Tokue Y, Matsumura Y, Katsumata N et al (1998) CD44 variant isoform expression and breast cancer prognosis. Jpn J Cancer Res 89:283–290PubMed

44.

Friedrichs K, Franke F, Lisboa BW et al (1995) CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55:5424–5433PubMed

45.

Foekens JA, Dall P, Klijn JG et al (1999) Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 84:209–215PubMedCrossRef

46.

Watanabe O, Kinoshita J, Shimizu T et al (2005) Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer. J Exp Clin Cancer Res 24:75–82PubMed

47.

Kristiansen G, Winzer KJ, Mayordomo E et al (2003) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9:4906–4913PubMed

48.

Kristiansen G, Schluns K, Yongwei Y et al (2003) CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88:231–236PubMedCrossRef

49.

Kristiansen G, Denkert C, Schluns K et al (2002) CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161:1215–1221PubMed

50.

Kristiansen G, Pilarsky C, Pervan J et al (2004) CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58:183–192PubMedCrossRef

51.

Yang GP, Ross DT, Kuang WW et al (1999) Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res 27:1517–1523PubMedCrossRef

52.

Nestl A, Von Stein OD, Zatloukal K et al (2001) Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61:1569–1577PubMed

53.

Dupont VN, Gentien D, Oberkampf M et al (2007) A gene expression signature associated with metastatic cells in effusions of breast carcinoma patients. Int J Cancer 121:1036–1046PubMedCrossRef

54.

Aigner S, Ramos CL, Hafezi-Moghadam A et al (1998) CD24 mediates rolling of breast carcinoma cells on P-selectin. Faseb J 12:1241–1251PubMed

55.

Schabath H, Runz S, Joumaa S et al (2006) CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119:314–325PubMedCrossRef

56.

Baumann P, Cremers N, Kroese F et al (2005) CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65:10783–10793PubMedCrossRef

57.

Brawley C, Matunis E (2004) Regeneration of male germline stem cells by spermatogonial dedifferentiation in vivo. Science 304:1331–1334PubMedCrossRef

58.

Nakagawa T, Nabeshima Y, Yoshida S (2007) Functional identification of the actual and potential stem cell compartments in mouse spermatogenesis. Dev Cell 12:195–206PubMedCrossRef

59.

Okita K, Ichisaka T, Yamanaka S (2007) Generation of germline-competent induced pluripotent stem cells. Nature 448:313–317PubMedCrossRef

60.

Wernig M, Meissner A, Foreman R et al (2007) In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 448:318–324PubMedCrossRef

61.

Maherali N, Sridharan R, Xie W et al (2007) Directly reprogrammed fibroblasts show global epigenetic remodelling and widespread tissue contribution. Cell Stem Cell 1:55–70CrossRefPubMed

62.

Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 1: 571–573CrossRef

63.

Kaplan RN, Rafii S, Lyden D (2006) Preparing the “soil”: the premetastatic niche. Cancer Res 66:11089–11093PubMedCrossRef

64.

Kaplan RN, Riba RD, Zacharoulis S et al (2005) VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820–827PubMedCrossRef

65.

Hiratsuka S, Watanabe A, Aburatani H et al (2006) Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8:1369–1375PubMedCrossRef

66.

Hiratsuka S, Nakamura K, Iwai S et al (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289–300PubMedCrossRef

67.

Hirakawa S, Kodama S, Kunstfeld R et al (2005) VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201:1089–1099PubMedCrossRef

68.

Qian CN, Berghuis B, Tsarfaty G et al (2006) Preparing the “soil”: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Cancer Res 66:10365–10376PubMedCrossRef

69.

Hirakawa S, Brown LF, Kodama S et al (2006) VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109:1010–1017PubMedCrossRef

70.

Eccles S, Paon L, Sleeman JP (2007) Lymphatic metastasis: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis

71.

Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells Cancer Cell 11:69–82PubMedCrossRef

72.

Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33(Suppl): 245–254PubMedCrossRef

73.

Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692PubMedCrossRef

74.

Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116PubMedCrossRef

75.

Eden A, Gaudet F, Waghmare A et al (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300:455PubMedCrossRef

76.

Fraga MF, Ballestar E, Villar-Garea A et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400PubMedCrossRef

77.

Hendrix MJ, Seftor EA, Seftor RE et al (2007) Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 7:246–255PubMedCrossRef

78.

Widschwendter M, Fiegl H, Egle D et al (2007) Epigenetic stem cell signature in cancer. Nat Genet 39:157–158PubMedCrossRef

79.

Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–856PubMedCrossRef

80.

Liu S, Dontu G, Mantle ID et al (2006) Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66:6063–6071PubMedCrossRef

81.

Prince ME, Sivanandan R, Kaczorowski A et al (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:973–978PubMedCrossRef

82.

Lessard J, Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423:255–260PubMedCrossRef

83.

Cui H, Ma J, Ding J et al (2006) Bmi-1 regulates the differentiation and clonogenic self-renewal of I-type neuroblastoma cells in a concentration-dependent manner. J Biol Chem 281:34696–34704PubMedCrossRef

84.

Mishra L, Shetty K, Tang Y et al (2005) The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 24:5775–5789PubMedCrossRef

85.

Polyak K, Hu M (2005) Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 10:231–247PubMedCrossRef

86.

Prindull G (2005) Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells? Exp Hematol 33:738–746PubMedCrossRef

87.

Ein-Dor L, Kela I, Getz G et al (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21:171–178PubMedCrossRef

88.

Fan C, Oh DS, Wessels L et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560–569PubMedCrossRef

Title: New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment
Authors: Jonathan P. Sleeman
Natascha Cremers
Publication date: 01-11-2007
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 8/2007
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-007-9122-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2007

Pre-EMTing metastasis? Recapitulation of morphogenetic processes in cancer

TGF-β and BMP7 interactions in tumour progression and bone metastasis

Understanding h-prune biology in the fight against cancer

Bone metastasis: pathogenesis and therapeutic implications

Functional pathways shared by liver and lung metastases: a mitochondrial chaperone machine is up-regulated in soft-tissue breast cancer metastasis

Rho GTPases: functions and association with cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer